BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37024570)

  • 1. A guide to the collection of T-cells by apheresis for ATMP manufacturing-recommendations of the GoCART coalition apheresis working group.
    Worel N; Holbro A; Vrielink H; Ootjers C; Le Poole K; Beer-Wekking I; Rintala T; Lozano M; Bonig H
    Bone Marrow Transplant; 2023 Jul; 58(7):742-748. PubMed ID: 37024570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of defined apheresis collection criteria in publicly available CAR-T cell clinical trial descriptions: Comprehensive review of over 600 studies.
    Thibodeaux SR; Aqui NA; Park YA; Schneiderman J; Su LL; Winters JL; Zubair AC; Schwartz J; Liu HD;
    J Clin Apher; 2022 Jun; 37(3):223-236. PubMed ID: 35085413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation and operational management of marketed chimeric antigen receptor T cell (CAR-T Cell) therapy-a guidance by the GoCART Coalition Pharmacist Working Group.
    Nezvalova-Henriksen K; Langebrake C; Bauters T; Moreno-Martinez ME; Ahnfelt E; Ekelund H; Domingos V; Pires V; Bonnin A; Bojanić I; Cabrerizo Y; Terwel S; Tam A
    Bone Marrow Transplant; 2023 Oct; 58(10):1069-1074. PubMed ID: 37528237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing leukapheresis in adult and pediatric patients eligible for chimeric antigen receptor T-cell therapy: suggestions from an Italian Expert Panel.
    Leone G; Baldini V; Bramanti S; Crocchiolo R; Gattillo S; Ermini S; Giudice V; Ferrero I; Moscato T; Milani R; Gozzer M; Piccirillo N; Tassi C; Tassi V; Coluccia P
    Blood Transfus; 2023 Nov; 21(6):514-525. PubMed ID: 37146295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unstimulated apheresis for chimeric antigen receptor manufacturing in pediatric/adolescent acute lymphoblastic leukemia patients.
    Jarisch A; Rettinger E; Sörensen J; Klingebiel T; Schäfer R; Seifried E; Bader P; Bonig H
    J Clin Apher; 2020 Sep; 35(5):398-405. PubMed ID: 32750197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy.
    Jo T; Yoshihara S; Hada A; Arai Y; Kitawaki T; Ikemoto J; Onomoto H; Sugiyama H; Yoshihara K; Obi N; Matsui K; Niwa N; Nakagawa Y; Kanda J; Kondo T; Saida S; Kato I; Hiramatsu H; Adachi S; Takita J; Takaori-Kondo A; Nagao M
    Transplant Cell Ther; 2022 Jul; 28(7):365.e1-365.e7. PubMed ID: 35460928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apheresis collection of mononuclear cells for chimeric-antigen receptor therapies.
    Maitta RW
    Eur J Haematol; 2024 Jan; 112(1):36-40. PubMed ID: 37525900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of cell collection efficiency in non-mobilized adult donors for autologous chimeric antigen receptor T-cell manufacturing.
    Piñeyroa JA; Cid J; Vlagea A; Carbassé G; Henao P; Bailo N; Ortiz-Maldonado V; Martínez-Cibrian N; Español M; Delgado J; Urbano-Ispizua Á; Lozano M
    Vox Sang; 2023 Mar; 118(3):217-222. PubMed ID: 36516201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma.
    Ceppi F; Rivers J; Annesley C; Pinto N; Park JR; Lindgren C; Mgebroff S; Linn N; Delaney M; Gardner RA
    Transfusion; 2018 Jun; 58(6):1414-1420. PubMed ID: 29536556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Manufacturing chimeric antigen receptor T cells: issues and challenges.
    Roddie C; O'Reilly M; Dias Alves Pinto J; Vispute K; Lowdell M
    Cytotherapy; 2019 Mar; 21(3):327-340. PubMed ID: 30685216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of CAR-T cell therapy on apheresis services: a Scottish perspective.
    Horne GA; Laird J; Latif AL; Irvine D; Wilson M; Douglas K
    J Clin Apher; 2021 Jun; 36(3):513-515. PubMed ID: 33378123
    [No Abstract]   [Full Text] [Related]  

  • 14. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.
    Sommer C; Boldajipour B; Kuo TC; Bentley T; Sutton J; Chen A; Geng T; Dong H; Galetto R; Valton J; Pertel T; Juillerat A; Gariboldi A; Pascua E; Brown C; Chin SM; Sai T; Ni Y; Duchateau P; Smith J; Rajpal A; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
    Mol Ther; 2019 Jun; 27(6):1126-1138. PubMed ID: 31005597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor Structure and Manufacturing of Clinical Grade CAR Engineered Cells using Different Bioreactors.
    Syed F; El Fakih R; Alahmari AD; Osman Ali AS; Aljurf M
    Hematol Oncol Stem Cell Ther; 2022 Nov; 15(3):137-152. PubMed ID: 36395497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of lymphapheresis for manufacturing autologous CAR-T cells.
    Yamanaka I; Yamauchi T; Henzan T; Sakoda T; Miyamoto K; Mishima H; Ono H; Koga Y; Nakashima Y; Kato K; Miyamoto T; Mizuno S; Ogawa Y; Ohga S; Akashi K; Maeda T; Kunisaki Y
    Int J Hematol; 2021 Oct; 114(4):449-458. PubMed ID: 34275066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical investigation of CAR T cells for solid tumors: Lessons learned and future directions.
    Bagley SJ; O'Rourke DM
    Pharmacol Ther; 2020 Jan; 205():107419. PubMed ID: 31629009
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells.
    Holzinger A; Abken H
    Pharmacology; 2022; 107(9-10):446-463. PubMed ID: 35696994
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apheresis for chimeric antigen receptor T-cell production in adult lymphoma patients.
    Harrer DC; Heidenreich M; Fante MA; Müller V; Haehnel V; Offner R; Burkhardt R; Herr W; Edinger M; Wolff D; Thomas S; Brosig A
    Transfusion; 2022 Aug; 62(8):1602-1611. PubMed ID: 35851959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.